BofA/Merrill Lynch Downgrades Regeneron Pharma (REGN) to Underperform
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $803.23 -0.34%
Rating Summary:
29 Buy, 19 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
29 Buy, 19 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
BofA/Merrill Lynch downgraded Regeneron Pharma (NASDAQ: REGN) from Neutral to Underperform, price target raised by $4 to $62.
For more ratings news on Regeneron Pharma click here and for the rating history of Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $72.19 yesterday.
For more ratings news on Regeneron Pharma click here and for the rating history of Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $72.19 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Regeneron Pharma (REGN) PT Raised to $756 at Bernstein SocGen Group
- Brinker Int'l (EAT) PT Raised to $310 at BofA Securities
- Wolfe Research Downgrades T-Mobile (TMUS) to Peerperform
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
